Not applicableStudy completedNCT02864914
What this trial is testing
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 333,580